Medscape22d
Genetic Variability of Surfactant Protein-B and Respiratory Distress Syndrome: Clinical Implications
Initial surfactant replacement studies, wherein surfactant therapy was used to treat prematurely-born infants with the hope of minimizing the severity or preventing respiratory problems ...
Pharmabiz1mon
US FDA grants orphan drug designation to AlveoGene’s novel, inhaled gene therapy, AVG-002 for lethal neonatal surfactant protein B deficiency
Current treatments are mainly supportive, including mechanical ventilation and surfactant replacement, however these interventions ... AVG-002, a novel gene therapy, has been designed using our ...